Newsroom

Press Releases


New Fully Customizable Electroporation System Enables Large-Scale Cell Therapy Development and Clinical Manufacturing

 

Gibco CTS Xenon Electroporation System complements Thermo Fisher Scientific’s portfolio of end-to-end cell therapy solutions



CARLSBAD, Calif., March 16, 2022 – Thermo Fisher Scientific, the world leader in serving science, has introduced a new large-volume electroporation system that allows cell therapy developers to more easily move from clinical development to commercial manufacturing. The Gibco CTS Xenon Electroporation System leverages a closed, highly flexible design to facilitate gene modifications without the use of traditional viral vectors. The electroporation approach enables the introduction of a payload into a cell by temporarily increasing cell permeability using an electrical pulse.

 

Unlike existing large-volume cell therapy electroporation solutions on the market, the Gibco CTS Xenon Electroporation System features programmable, flexible electroporation conditions, offering cell therapy developers full control to optimize a variety of hard-to-transfect cell types and payloads. The system may be used as a standalone technology or integrated with the Gibco CTS Rotea Counterflow Centrifugation System as part of a modular, closed and automated cell therapy manufacturing workflow.

 

“We launched the CTS Rotea System in 2020 as part of our strategy to deliver fit-for-purpose cell therapy solutions that can easily scale from development to commercialization. Adding the CTS Xenon Electroporation System to our end-to-end workflow will help customers overcome manufacturing challenges that hinder production, enabling them to bring life-saving therapies to patients faster,” said Amy Butler, president of biosciences, Thermo Fisher Scientific.

 

The CTS Xenon Electroporation System can transfect up to 2.5e9 cells in 25 mL in a sterile system, enabling rapid and efficient non-viral transfection for clinical manufacturing applications. In addition, it delivers up to 80% cell viability and 90% gene knockout transfection to seamlessly scale from the small-volume Neon Transfection System without the need for re-optimization of electroporation parameters.

 

As a Cell Therapy Systems (CTS) solution, the Xenon Electroporation System is designed to easily transition from the bench to the clinic. Thermo Fisher’s CTS product line offers a comprehensive portfolio of GMP-manufactured products backed by regulatory documentation and designed to work synergistically across the entire workflow, from cell isolation/activation to cell engineering and expansion, to address cell therapy developers’ manufacturing needs.

 

To learn more about the Gibco CTS Xenon Electroporation System, visit www.thermofisher.com/xenon.

 

To learn more about Thermo Fisher’s scalable, end-to-end cell therapy manufacturing solutions, visit www.thermofisher.com/celltherapy.

New Fully Customizable Electroporation System

Mar 16, 2022

Gibco CTS Xenon Electroporation System complements Thermo Fisher Scientifics portfolio of end-to-end cell therapy solutions (Photo: Business Wire)


About Thermo Fisher Scientific

 

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Media contact information:

 

Mauricio Minotta
760-805-5266
mauricio.minotta@thermofisher.com

 

Jessika Parry
419-266-4016
jparry@greenough.biz

 


 

SOURCE Thermo Fisher Scientific

 

If you have any questions regarding this Press Release, please email us at media.relations@thermofisher.com.